Understanding risks of infections and mortality after CAR T-cell therapy
Modeling Risk for Hypogammaglobulinemia, Infections, and Mortality with Chimeric Antigen Receptor (CAR) T-cell Therapy
This study is looking at how CAR T-cell therapy might affect your immune system, especially if it leads to low antibody levels, and it aims to find ways to help doctors better support patients like you after treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11093381 on NIH RePORTER |
What this research studies
This research investigates the immunologic risks associated with chimeric antigen receptor (CAR) T-cell therapy, particularly focusing on hypogammaglobulinemia, a condition characterized by low levels of antibodies. The study will analyze a large group of patients who have undergone CAR T-cell therapy to identify risk factors for infections and poor health outcomes. By employing advanced statistical methods, including regression models and Bayesian analysis, the research aims to develop a clinical risk prediction model that can help healthcare providers better manage and support patients post-therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals over 21 years old who have received CAR T-cell therapy and may be experiencing immunologic complications.
Not a fit: Patients who have not undergone CAR T-cell therapy or those with unrelated immunologic conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved management strategies for patients undergoing CAR T-cell therapy, potentially reducing the risk of infections and improving overall health outcomes.
How similar studies have performed: Previous research has shown promising results in understanding immunologic outcomes in patients treated with B-cell targeted therapies, suggesting that this approach may yield valuable insights.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Barmettler, Sara — Massachusetts General Hospital
- Study coordinator: Barmettler, Sara
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.